Composition for improving the effective field of view

Abstract

To clarify the effects of fermented papaya products on drivers, particularly on their field of vision, and to provide a composition for improving field of vision. [Solution] The composition of the present invention is a composition for improving effective field of vision, containing fermented papaya food as an active ingredient.

Description

[Technical Field]

[0001] This invention relates to a composition for improving the effective field of view. [Background technology]

[0002] Fermented papaya products, produced by fermenting unripe Carica papaya (Carica papaya Linn) with sugar and edible yeast, increase in maltose and maltotriose when mixed with saliva compared to when mixed with water.

[0003] FPP (registered trademark) is a fermented papaya preparation manufactured and sold by Osato International (Patent Document 1). FPP (registered trademark) is a granular fermented food with a natural sweetness, manufactured in a facility in Japan that has obtained international standards ISO9001 (quality), ISO14001 (environment), ISO22000 (food safety), and FSSC22000 (food safety system). Furthermore, it has obtained the international anti-doping certification program "Informed Sport," and is evaluated as a highly safe food for athletes. In fact, since 2005, it has been used for the health management of the prestigious British Aston Martin Racing as an official partner, and in a demonstration study targeting racing drivers at the 24 Hours of Le Mans, its effect in reducing oxidative stress was confirmed (Non-Patent Document 1).

[0004] Previous clinical studies have shown that continuous consumption of fermented papaya products has antioxidant, anti-inflammatory, and immunomodulatory effects through activation of the Nrf2 pathway (Non-Patent Literature 2). Furthermore, its effectiveness has been reported in improving immune function in patients with type 2 diabetes, improving fatigue, headaches, insomnia, and cognitive decline (short-term memory and concentration) associated with electromagnetic hypersensitivity, and reducing oxidative stress and improving motor symptoms associated with Alzheimer's disease and Parkinson's disease, among other symptoms related to chronic inflammation (Non-Patent Literature 3-6). Fermented papaya products, while primarily composed of carbohydrates, do not adversely affect blood glucose levels, and their usefulness as a metabolizable energy source has been confirmed even in patients with type 2 diabetes (Non-Patent Literature 7). A US patent for "treatment for patients with type 2 diabetes" was obtained in 2025 (Patent Literature 2).

[0005] On the other hand, in recent years, the automobile transport industry has been facing a serious labor shortage due to the aging of professional drivers, including truck, bus, and taxi drivers (Non-Patent Literature 8, 9). Factors contributing to this include a decline in driving skills due to aging, delayed recovery from fatigue, and increased health risks. In addition to conventional external evaluation methods such as driving simulators, there is a growing need for comprehensive and endogenous health management from before employment to after employment (Non-Patent Literature 10). [Prior art documents] [Patent Documents]

[0006] [Patent Document 1] Japanese Patent Publication No. 2011-041478 [Patent Document 2] US12324822B2 [Non-patent literature]

[0007] [Non-Patent Document 1] Mantello,P., Hayashi,Y., Garrel,C., Aruma,OI, Kaur,H.(2007). Aston Martin RacingLe Mans 2007: Follow up of Oxidative Stress of 3 Racers (DBR9 #009) during 24Hours Race.

Outdoor Tool2

Outdoor Tools3

Outdoor Tools 4

Non-Patent Document 5

Non-Patent Document 6

Non-Patent Document 7

Non-Patent Document 13

Non-Patent Document 14

Non-Patent Document 15

[0008] An object of the present invention is to clarify the effects of papaya fermented food on drivers, particularly the effects on the effective visual field, and to provide a composition for improving the effective visual field. [Means for Solving the Problems]

[0009] The inventors verified the effects of continuous intake of papaya fermented food for one month on the health related to driving skills such as effective visual field and fatigue recovery after work in active bus drivers belonging to Izuhakone Bus Co., Ltd.

[0010] The present disclosure provides, for example, the following inventions. [1] A composition for improving an effective visual field, containing a papaya fermented food as an active ingredient. [2] The composition according to [1], which improves the driving ability of a vehicle. [3] The composition according to [1] or [2], which reduces drowsiness and / or fatigue. [4] The composition according to any one of [1] to [3], which improves concentration. [5] The composition according to [2], wherein the driving ability includes at least one selected from maintaining wakefulness, cognitive ability, judgment ability, and reactivity during driving. [6] The composition according to any one of [1] to [5], which further reduces urinary 8-hydroxydeoxyguanosine (8-OHdG) in a subject. [7] The composition according to [6], which reduces oxidative stress in a subject. [8] The composition according to any one of [1] to [7], which is a pharmaceutical composition or a food composition. [9] The composition according to any one of [1] to [7], wherein the dosage of the papaya fermented food is 0.5 to 30 g / day for an adult weighing 70 kg.

[10] The composition according to any one of [1] to [9], which is continuously ingested or administered for one month or more.

[11] The composition according to any one of [1] to

[10] , which is intended for humans aged 45 or older.

[12] A method for evaluating changes in the effective field of view of a subject, comprising measuring changes in 8-hydroxydeoxyguanosine (8-OHdG) in the subject's urine. [Effects of the Invention]

[0011] According to the present invention, it is possible to provide a composition for improving effective field of vision, which contains fermented papaya food as an active ingredient. [Brief explanation of the drawing]

[0012] [Figure 1] This graph shows the effect of FPP (registered trademark) intake on subjective symptoms. [Figure 2] This graph shows the impact of FPP (registered trademark) intake on health-related quality of life (SF-12 (registered trademark)). [Figure 3] This graph shows the effect of FPP (registered trademark) intake on the urinary 8-OHdG levels of each subject. [Figure 4] This graph shows the effect of FPP(registered trademark) intake on salivary amylase activity in each subject. [Figure 5] This graph shows the effect of FPP (registered trademark) intake on salivary cortisol levels in each subject. [Figure 6] This graph shows the effect of FPP (registered trademark) intake on the reaction time of each subject's central visual field. [Figure 7] This graph shows the effect of FPP (registered trademark) intake on the reaction time of each subject's peripheral vision. [Modes for carrying out the invention]

[0013] One embodiment of the composition is a composition for improving effective field of vision, containing fermented papaya food as an active ingredient.

[0014] Papaya (scientific name: Carica papaya Linn) is a plant belonging to the Papayaceae family, native to Central and South America, and its fruit is consumed as a tropical fruit. Fermented papaya products are fermented products derived from papaya, produced by fermenting unripe Carica papaya Linn fruit with sugar and edible yeast.

[0015] The fermented papaya product is preferably FPP (registered trademark) manufactured by Osato Laboratory Co., Ltd. and sold by Osato International Co., Ltd. This FPP (registered trademark) is available as "FPPFermented Papaya Preparation" (registered trademark) or "Immun'Age" (registered trademark). This FPP is certified to ISO9001:2015, ISO14001:2015, and ISO22000:2018, and is produced in a factory that was the first in Japan to obtain FSSC22000, which is considered the strictest food safety standard in Europe and the United States, thus guaranteeing quality, environmental friendliness, and safety.

[0016] According to analysis by the Japan Food Research Laboratories, FPP (registered trademark) contains 91.2g of carbohydrates per 100g, along with small amounts of protein (0.3g), potassium (14.9mg), and water (8.5g) (Lot No. 091; analysis test report dated May 27, 2014). In the same lot, the lipid content per 100g of FPP (registered trademark) is 0g.

[0017] Fermented papaya food can be produced by fermenting unripe Carica papaya fruit with sugar and edible yeast, as described above. The composition of this disclosure can be appropriately prepared in various forms such as granules, powders, and fine granules to be suitable for oral intake, and additives such as excipients, binders, and lubricants can be added as appropriate during preparation.

[0018] In this specification, "Useful Field of View (UFOV)" refers to the area in which information can be processed while simultaneously focusing on a central point. The UFOV can vary from person to person and may fluctuate depending on physical condition, concentration level, and age. A narrowed UFOV can lead to traffic accidents, such as overlooking important objects. Furthermore, reaction speed within the UFOV is also a crucial factor in traffic safety.

[0019] In this specification, "improvement of effective field of view" means a reduction in reaction time within the effective field of view. The reaction time within the effective field of view can be measured, for example, by the method shown in the examples. Specifically, this includes an effective field of view test using software that responds to changes in central and peripheral vision using a tablet device. This test can be measured on a desk and involves focusing on a dot on the inner circle (central field of view: corresponding to a preceding vehicle) while also paying attention to eight dots on the outer circle (peripheral field of view: corresponding to pedestrians, traffic signals, roadside objects, etc.). During the test, the dots on the inner or outer circle expand randomly. Measurement is performed at a distance of approximately 40 cm from the screen, and the "inner" or "outer" button is touched when the dot expansion is noticed. The reaction time to the start of target expansion in both the central and peripheral fields of view is measured as an indicator of cognitive processing speed. Improvement of the effective field of view can be evaluated by the reduction in cognitive processing speed (reaction time) in the central and / or peripheral fields of view. Alternatively, evaluation may be performed using an effective field of view measurement system developed by, for example, Nissan Motor Co., Ltd. Here, improvement in the effective field of view may be evaluated by measuring the difference in reaction time before and after ingestion of fermented papaya food in the same individual, or by measuring the difference in the average reaction time in a group consisting of multiple individuals (for example, 2 or more people, 3 or more people, 5 or more people, 10 or more people, etc.).

[0020] Consumption of fermented papaya products, especially through continuous consumption over a certain period, tends to shorten reaction time in the effective field of vision, thereby improving driving ability. In addition, it tends to reduce drowsiness and / or fatigue and improve concentration. Here, driving ability includes at least one selected from maintaining alertness, perception, judgment, and responsiveness while driving. Perception, judgment, and responsiveness mainly refer to the ability to perceive and judge other vehicles, traffic signals, bicycles, pedestrians, roadsides, obstacles, etc., and to react to them when driving a car.

[0021] Furthermore, continuous consumption of fermented papaya products over a certain period has been shown to have significant effects in improving wakefulness, reducing drowsiness during work, lack of concentration, irritability, fatigue, post-work fatigue, sleep quality, headaches, back pain, stiff shoulders, cravings for sweets (sugar cravings), bowel movements, and ease of falling asleep.

[0022] Continuous consumption of fermented papaya products over a certain period also leads to improvements in health-related quality of life (QOL). In particular, significant improvements were observed in three items of the SF-12® (Short Form-12): overall health perception, vitality, and mental health.

[0023] The composition of one embodiment reduces 8-hydroxydeoxyguanosine (8-OHdG) in the urine of the target subject. Here, the reduction of 8-OHdG means that, for the same individual, the urinary 8-OHdG after ingestion of the fermented papaya food is reduced compared to the urinary 8-OHdG before ingestion. This can also be evaluated using the average value in a group consisting of multiple individuals (e.g., 2 or more people, 3 or more people, 5 or more people, 10 or more people, etc.). The method for measuring 8-OHdG is not particularly limited, and conventional methods such as HPLC-ECD, ELISA, and highly sensitive LC-MS / MS methods can be used.

[0024] 8-OHdG is a compound formed when guanine bases in DNA are oxidized by reactive oxygen species, and is a molecule produced when genes are damaged. Because it is excreted in urine, it is widely used as a biomarker indicating the degree of oxidative stress in the body. By ingesting the composition of this embodiment, oxidative stress in the subject is reduced, especially by continuous intake over a certain period. Furthermore, it has been shown that there is a correlation between the reduction of 8-OHdG in urine and the improvement of effective field of vision in subjects who ingested fermented papaya food for a certain period.

[0025] The composition of one embodiment reduces salivary amylase activity and / or salivary cortisol. Since salivary amylase activity tends to increase when under mental stress, salivary amylase activity is used to assess the degree of stress as a marker indicating the activity of the autonomic nervous system. Salivary amylase activity can be easily measured using a salivary amylase monitor. Salivary cortisol is also one of the indicators of the strength of the stress response. Salivary cortisol can be measured by immunoassays such as ELISA. Reducing salivary amylase activity and / or salivary cortisol suggests a reduction in stress.

[0026] The compositions disclosed herein may be food compositions or pharmaceutical compositions, and are particularly preferably food compositions. Fermented papaya food, such as FPP®, has been sold and consumed as food for many years and is safe for human consumption. The subjects to whom the compositions disclosed herein can be applied are not particularly limited, but are preferably those who drive a car on a daily basis, such as professional drivers and those who drive a car to work or school. Particularly preferred are middle-aged and elderly people aged 45 and over, such as those aged 45 to under 65, 65 to under 75, and 75 and over.

[0027] The amount of the composition disclosed herein used may be 0.5 to 30 g / day for an adult weighing 70 kg, based on the amount of fermented papaya food as the active ingredient, preferably 1 to 20 g / day, more preferably 3 to 15 g / day, and most preferably 3 to 9 g / day.

[0028] FPP may be taken or administered 1 to 5 times a day, preferably 1 to 3 times a day, and more preferably 2 times a day. The timing of intake may be after waking up, before meals, after meals, between meals, or before going to bed.

[0029] The compositions of this disclosure are preferably consumed continuously over a certain period of time, for example, continuously for two weeks or more, three weeks or more, one month or more, two months or more, three months or more, or six months or more.

[0030] The evaluation method disclosed herein may be a method for evaluating changes in the effective field of view of a subject, comprising measuring changes in urinary 8-hydroxydeoxyguanosine (8-OHdG) of the subject. As demonstrated in the examples described below, there is a correlation between a decrease in urinary 8-OHdG and an improvement in the effective field of view. Therefore, urinary 8-OHdG is considered useful as a novel biomarker for evaluating the effective field of view. In this evaluation method, urinary 8-OHdG is measured in the same subject at different times, and if urinary 8-OHdG decreases (i.e., the change in urinary 8-OHdG is negative), the effective field of view may be evaluated as having improved; if urinary 8-OHdG increases (i.e., the change in urinary 8-OHdG is positive), the effective field of view may be evaluated as having deteriorated; and if there is no change in urinary 8-OHdG, the effective field of view may be evaluated as having not changed. In other words, by regularly monitoring the urinary 8-OHdG of a subject, changes in the effective field of view can be evaluated and understood. [Examples]

[0031] (Materials and Methods) 1. Target This study was conducted from December 2024 to March 2025, involving 23 active bus drivers (20 males, 3 females, aged 22-61, average age 49.6) belonging to Izu Hakone Bus Co., Ltd. Participants were given verbal and written explanations of the research, and were informed that participation was voluntary, that declining participation would not affect their performance evaluations or treatment at their respective companies, and that their privacy would be respected. Their consent was obtained before the study was conducted. This research was approved by the Ethics Review Committees of the Osato Institute and Nagoya University.

[0032] 2. Research Design This study is a prospective, single-group intervention study that evaluates the effects of continuous intake of FPP® on fatigue and health-related indicators in healthy occupational drivers using non-invasive methods. Participants continuously took 3g of FPP® three times a day (upon waking, during work, and before bedtime), for a total of 9g / day, for one month. The following items were evaluated two weeks before the start of intake (Day -14), on the start day (Day 0), two weeks later (Day 14), and one month later (Day 28). The mean values ​​on Day -14 and Day 0 were used as the baseline.

[0033] 3. Questionnaire survey Subjective health status was assessed using a 15-item self-administered questionnaire that included wakefulness, sleepiness, concentration, fatigue, and sleep quality. Fatigue-related symptoms and work performance were evaluated using a 5-point scale. Health-related quality of life (QOL) was assessed using the SF-12® (Short Form-12). The questionnaires were administered anonymously, and each participant was assigned a sequential number to enable follow-up.

[0034] 4.Biochemical indicators As indicators of physical and mental stress, urinary 8-hydroxydeoxyguanosine (8-OHdG), salivary amylase activity, and cortisol concentration were measured. Urine samples were collected upon waking, stored at -20°C, and analyzed at the Japan Institute for Aging Control. Saliva samples were collected during visual field testing after arriving at work, stored at -20°C, and measured at the Osato Laboratory using a salivary amylase monitor (Nipro Co., Japan) and a Cortisol Salivary Immunoassay Kit (Salimetrics LLC, USA).

[0035] 5. Effective visual field testing Dynamic effective field of view (UFOV) measurement was performed using a tablet device (iPad Air 10.9-inch) with software that responds to changes in central and peripheral vision. This test can be measured on a desk and involves a task in which the participant fixates on a dot on the inner circle (central vision: corresponding to a preceding vehicle) while also paying attention to eight dots on the outer circle (peripheral vision: corresponding to pedestrians, traffic signals, roadside objects, etc.). During the test, the dots on the inner or outer circle expand randomly. Measurement was performed at a distance of approximately 40 cm from the screen, and the participant touched the "inner" or "outer" button when they noticed the dot expanding. The reaction time to the start of target expansion in both the central and peripheral vision was measured as an indicator of cognitive processing speed.

[0036] (result) 1. Subjective health indicators This study obtained 23 participants, but ultimately 21 participants in the intervention group were included in the analysis. Figure 1 summarizes the results of a self-administered questionnaire evaluating subjective health perceptions regarding fatigue after one month of continuous intake of FPP®. The scores were evaluated on a 5-point scale, as shown in Table 1. [Table 1]

[0037] In each item shown in Figure 1, "Ease of waking up" *1 "Drowsiness during work" *1, Lack of concentration *2 , Irritability *2 , Tiredness *1 , "Fatigue after work and sleep quality" *1 , "Headache, low back pain, and shoulder stiffness" *2 , and "Desire for sweetness (sugar craving)" *2 showed significant improvement ( *1 p < 0.01, *2 p < 0.05, vs. baseline). Regarding "bowel movement" and "ease of falling asleep", significant improvement was observed only 2 weeks after intake (p < 0.05, vs. baseline).

[0038] Figure 2 shows the evaluation results of health-related QOL. In the SF-12 (registered trademark) for evaluating health-related QOL, significant improvement was observed in the three items of "general health perception" *1 , "vitality" *2 , and "mental health" *1 ( *1 p < 0.01, *2 p < 0.05, vs. Day 0). Furthermore, in the four items of "general health perception", "vitality", "social life function", and "mental health", scores exceeded the Japanese standard values.

[0039] 2. Biochemical indicators The urinary 8-OHdG value decreased in 13 out of 21 (61.9%) FPP (registered trademark) takers 1 month after the start of intake, showing an overall improvement trend (Figure 3). On the other hand, among the 8 (38.1%) who showed an increase, 5 were within the standard range (4.6 - 23.6 ng / kg / h) defined by the Japan Institute of Aging Control. <00,00246>

[0040] In the entire test group, a significant decrease in the urinary 8-OHdG value was observed from 2 weeks to 4 weeks after intake (Table 2, p = 0.039 Day 14 vs. Day 28). Also, subjects aged 45 and above showed higher values compared to subjects under 45 (younger group), but showed lower values than the younger group 1 month later (Table 3, p = 0.035 Day 14 vs. Day 28). [Table 2] [Table 3]

[0041] Salivary amylase activity decreased in 9 out of 21 participants (42.9%), but no significant change was observed (Figure 4). Of the 12 participants who showed an increase, 7 were within the normal range (45 KU / L or less). The average values ​​for salivary amylase activity across all test groups are shown in Table 4. [Table 4]

[0042] Furthermore, salivary cortisol levels decreased in 9 out of 20 participants (45.0%), but the difference was not statistically significant (Figure 5). Of the 11 participants who showed an increase, 5 were within the normal range (0.149 to 0.739 μg / dl or less). The mean salivary cortisol levels for the entire test group are shown in Table 5. [Table 5]

[0043] 3. Effective visual field testing Continuous intake of FPP (registered trademark) for one month resulted in a reduction and improvement in reaction time in the central visual field (Figure 6, p=0.127 vs. Day 0). Significant improvement was also observed in reaction time in the peripheral visual field (Figure 7, p=0.047 vs. Day 0). Of the 21 participants, 17 (81.0%) showed a reduction in reaction time, broken down into improvement in both visual fields (n=10), improvement in the central visual field only (n=3), or improvement in the peripheral visual field only (n=4) (Table 6). On the other hand, four participants showed no improvement in any visual field but showed an increase in reaction time. [Table 6]

[0044] Furthermore, urinary 8-OHdG levels were significantly reduced in (1) the group with improvement in both visual fields, (2) the group with improvement in both visual fields and central visual field only, and (3) the group with improvement in both visual fields and peripheral visual field only (Tables 7, 8, and 9). [Table 7] [Table 8] [Table 9]

[0045] Regarding the association with improved effective visual field, 11 out of 17 patients (64.7%) who showed improvement also showed a decrease in 8-OHdG levels, compared to only 1 out of 4 patients (25.0%) who did not show improvement (Table 10). Furthermore, no association was found between effective visual field and salivary amylase activity or salivary cortisol (data not shown). [Table 10]

[0046] (Consideration) This study investigated the effects of one month of continuous intake of FPP (registered trademark) on subjective health indicators, oxidative stress markers, and effective visual field (an aspect of cognitive function) in professional bus drivers. The study targeted professional drivers who regularly engage in driving duties, and the results of one month of continuous intake suggested that FPP (registered trademark) is safe to use and useful from the perspective of maintaining health status and driving performance, as well as preventing traffic accidents.

[0047] In the evaluation of subjective health indicators, significant improvements were observed in several items related to driving performance, including "drowsiness," "concentration," "fatigue," "sleep quality," and "wakefulness." In particular, sleep quality is known to be involved in maintaining homeostasis of the immune system and plays an important role in infection defense and inflammation suppression (Non-Patent Literature 11). Previous studies have reported that sleep deprivation impairs the function of innate and adaptive immunity, as well as increases the blood levels of inflammatory cytokines such as IL-6 and TNF-α, and may be a risk factor for a wide range of chronic diseases, including cerebrovascular and cardiovascular diseases, autoimmune diseases, and neurodegenerative diseases (Non-Patent Literature 12-14).

[0048] On the other hand, studies involving healthy elderly individuals have reported significant reductions in IL-6 and TNF-α, demonstrating that FPP (registered trademark) has anti-inflammatory and immunomodulatory effects (Non-Patent Literature 15). In addition, health-related QOL assessments using SF-12 (registered trademark) have confirmed significant improvements in physical and psychological health, including "overall health perception," "vitality," and "mental health." These findings suggest that continued intake of FPP (registered trademark) may contribute to reducing chronic fatigue and stress in professional drivers, and may contribute to maintaining and preventing long-term health problems through improved QOL in daily life and driving work.

[0049] This study targeted healthy individuals, and urinary 8-OHdG levels were within the normal range, but showed an increasing trend with age. Despite a short intervention period of one month, FPP (registered trademark) significantly reduced oxidative stress in middle-aged and elderly individuals, confirming its antioxidant effect. Oxidative stress is involved in the formation of various pathological conditions based on chronic inflammation, and has been reported to contribute to the onset and progression of arteriosclerosis, cerebrovascular and cardiovascular diseases, glaucoma, autoimmune diseases, and even Alzheimer's disease and Parkinson's disease (Non-patent documents 16, 17). Therefore, the improvement in urinary 8-OHdG levels in middle-aged and elderly individuals, which was more pronounced than in younger individuals, as revealed in this study, supports the preventive significance of FPP against oxidative stress-related diseases. Furthermore, it suggests the potential to contribute to maintaining the health necessary for safe driving, not only for professional drivers but for all individuals.

[0050] On the other hand, no significant changes were observed in salivary amylase and cortisol, indicators of psychological stress. This result may be due to the subjects' generally stable mental health, as well as the possibility that variability in saliva collection times due to work shifts may have affected the measurement results.

[0051] Effective visual field testing revealed an overall improvement trend in reaction times in both central and peripheral visual fields, with 17 out of 21 participants (81.0%) showing improvement in at least one visual field function. In particular, the reduction in reaction time in peripheral vision indicates an improvement in the ability to grasp the entire spatial field, which may contribute to the early detection of hazards and is thought to lead to improved safe driving. Furthermore, a decrease in urinary 8-OHdG was observed in 64.7% of the group that showed improvement in visual field, suggesting a correlation between reduced oxidative stress and improved visual field function. This study provides a new finding: 8-OHdG is a useful biochemical indicator that reflects the decline and recovery of visual field function.

[0052] On the other hand, for the group that did not show improvement in effective field of vision or oxidative stress, expanding the number of subjects and the intake period would allow for consideration of factors such as work environment and health status, which is thought to lead to improved scientific validity for maintaining safe driving. In addition, it was shown that FPP (registered trademark) intake may contribute to the maintenance and improvement of visuospatial cognitive function, that is, cognitive functions essential for driving, such as sign recognition and situational judgment. These functions are directly linked to the immediate judgment and response ability required of professional drivers and are thought to play an important role in accident prevention and maintaining safe driving.

[0053] Previous studies on FPP (registered trademark) have reported its effects in reducing oxidative stress under acute stress in racing drivers and improving immune function and inflammatory markers in patients with chronic inflammatory diseases. This study provides new insights into the potential of FPP (registered trademark) to contribute to fatigue reduction, improved quality of life, and maintenance of driving ability in professional drivers who are subjected to chronic physical stress.

[0054] Furthermore, improvements in subjective symptoms such as reduced drowsiness and fatigue, improved concentration and sleep quality, and alleviation of physical discomfort (headaches, stiff shoulders, etc.) are closely related to maintaining alertness, judgment, and responsiveness while driving, and are expected to improve the quality of driving work. Therefore, FPP (registered trademark) is considered effective as a complementary intervention not only for the health management of professional drivers, but also from the perspective of supporting safe driving and preventing traffic accidents.

[0055] FPP (registered trademark) is a preventive medicine approach that combines safety and practicality, and is expected to be one of the practical strategies that contribute to maintaining and improving health status at the pre-disease stage. Currently, a large-scale clinical trial is underway in collaboration with Florida State University in the United States, targeting general elderly drivers aged 75-80, with the aim of improving driving skills using FPP (registered trademark). The findings obtained from this study indicate the potential for contributing to the maintenance of driving skills through fatigue recovery in middle-aged and elderly individuals, and could serve as foundational evidence for the clinical application of FPP (registered trademark). Furthermore, since driving is directly linked to independence in daily life in rural areas, it is expected to be one of the solutions for realizing a society in which elderly people can continue to drive safely.

Claims

1. A composition for improving effective field of vision, containing fermented papaya food as an active ingredient.

2. The composition according to claim 1, which improves the driving ability of a car.

3. The composition according to claim 1, which reduces drowsiness and / or fatigue.

4. The composition according to claim 1, which improves concentration.

5. The composition according to claim 2, wherein the driving ability includes at least one selected from maintaining alertness during driving, cognitive ability, judgment ability, and responsiveness.

6. The composition according to claim 1, further reducing 8-hydroxydeoxyguanosine (8-OHdG) in the urine of the subject.

7. The composition according to claim 6, which reduces the oxidative stress of the target.

8. A composition according to any one of claims 1 to 7, which is a pharmaceutical composition or a food composition.

9. The composition according to any one of claims 1 to 7, wherein the dose of fermented papaya food is 0.5 to 30 g / day for an adult weighing 70 kg.

10. A method for assisting the evaluation of changes in the effective field of view of a subject, comprising measuring changes in 8-hydroxydeoxyguanosine (8-OHdG) in the subject's urine.

Images